Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Massachusetts General Hospital Brigham and Women's Hospital Beth Israel Deaconess Medical Center Pharmacia |
---|---|
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00146588 |
The purpose of this study is to find out what effects (good and bad) a combination of cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Condition | Intervention |
---|---|
Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer |
Drug: Cyclophosphamide Drug: Epirubicin Drug: Capecitabine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer |
Enrollment: | 55 |
Study Start Date: | April 2002 |
Estimated Study Completion Date: | September 2008 |
Primary Completion Date: | September 2004 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Dana-Farber Cancer Center | |
Boston, Massachusetts, United States, 02115 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Craig Bunnell, MD | Dana-Farber Cancer Institute |
Responsible Party: | Dana-Farber Cancer Institute ( Craig Bunnell, MD ) |
Study ID Numbers: | 02-036 |
Study First Received: | September 6, 2005 |
Last Updated: | August 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00146588 History of Changes |
Health Authority: | United States: Institutional Review Board |
Breast cancer cytoxan epirubicin capecitabine |
Antimetabolites Capecitabine Skin Diseases Immunologic Factors Breast Neoplasms Cyclophosphamide Epirubicin |
Immunosuppressive Agents Anti-Bacterial Agents Antineoplastic Agents, Alkylating Antirheumatic Agents Alkylating Agents Breast Diseases |
Antimetabolites Capecitabine Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Skin Diseases Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Breast Neoplasms Cyclophosphamide Antibiotics, Antineoplastic |
Epirubicin Immunosuppressive Agents Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Myeloablative Agonists Antineoplastic Agents, Alkylating Antirheumatic Agents Alkylating Agents Breast Diseases |